We are live on ! Find out more
EFTRW

eFFECTOR Therapeutics, Inc. Warrant
EFTRW

Delisted

EFTRW was delisted on the 2nd of July, 2024.

Back to rankings

38 hedge funds and large institutions have $5.23M invested in eFFECTOR Therapeutics, Inc. Warrant in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 4 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

46% more funds holding

Funds holding: 26 → 38 (+12)

44% more capital invested

Capital invested by funds: $3.62M → $5.23M (+$1.61M)

Holders
38
Holders Change
+12
Holders Change %
+46.15%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
4
Reduced
–
Closed
4
Calls
$294K
Puts
–
Net Calls
+$294K
Net Calls Change
+$132K

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$229K
2
QGA
Q Global Advisors
Texas
+$162K
3
GCL
Glazer Capital LLC
New York
+$133K
4
Citadel Advisors
Citadel Advisors
Florida
+$97.5K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$90.1K

Top Sellers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
-$170K
2
PAMP
Polar Asset Management Partners
Ontario, Canada
-$102K
3
WA
Whitebox Advisors
Minnesota
-$26.9K
4
SCM
Saba Capital Management
New York
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.27M – – –
AFM
2
Anson Funds Management
Texas
$1.08M – – –
LA
3
Linden Advisors
New York
$316K – – –
AC
4
Aristeia Capital
Connecticut
$283K +$229K +283,129 New
Citadel Advisors
5
Citadel Advisors
Florida
$201K +$97.5K +120,571 +151%
Balyasny Asset Management
6
Balyasny Asset Management
Illinois
$200K +$90.1K +111,434 +126%
QGA
7
Q Global Advisors
Texas
$200K +$162K +200,000 New
GCL
8
Glazer Capital LLC
New York
$164K +$133K +164,259 New
PC
9
Periscope Capital
Ontario, Canada
$142K – – –
MIM
10
Monashee Investment Management
Massachusetts
$133K – – –
BFM
11
Boothbay Fund Management
New York
$117K +$9.55K +11,814 New
SC
12
Sculptor Capital
New York
$108K – – –
Blackstone Inc
13
Blackstone Inc
New York
$100K – – –
FTCM
14
Fir Tree Capital Management
New York
$100K – – –
LP
15
LMR Partners
United Kingdom
$100K – – –
WP
16
Woodline Partners
California
$94K – – –
CH
17
CVI Holdings
Delaware
$67K – – –
PSAMP
18
P. Schoenfeld Asset Management (PSAM)
New York
$67K – – –
SCC
19
Spring Creek Capital
Kansas
$67K +$53.9K +66,666 New
CL
20
CSS LLC
Illinois
$65K +$52.2K +64,564 New
ACA
21
Arena Capital Advisors
California
$63K +$50.7K +62,690 New
AA
22
AQR Arbitrage
Connecticut
$45K +$36.4K +44,998 New
SCM
23
Segantii Capital Management
Hong Kong
$38K +$3.14K +3,886 New
ACM
24
Atalaya Capital Management
New York
$33K – – –
TCM
25
Tenor Capital Management
New York
$33K – – –
1
2

EFTRW Hedge Fund Activity: Q2 2021 in Review

38 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q2 2021, worth a combined $5.23M — up 44% from $3.62M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new EFTRW positions and 4 closed out — a net gain of 12 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $229K. The largest seller was Empyrean Capital Partners, exiting entirely with an estimated $170K sold.

  • 38 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q2 2021, up from 26 in Q1 2021.
  • Funds reported $5.23M of eFFECTOR Therapeutics, Inc. Warrant stock for Q2 2021, up 44% quarter-over-quarter.
  • 16 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q2 2021 and 4 closed out, a net change of +12 holders.
  • The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q2 2021 was Aristeia Capital, an estimated $229K added.
  • The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q2 2021 was Empyrean Capital Partners, an estimated $170K sold.

Based on aggregated 13F filings for Q2 2021.